Table 2.
Principal therapeutic interventions currently under investigation
| Treatment goal | Drug | Target |
|---|---|---|
| Anti-viral growth | Ritonavir, prezcobix | • HIV protease Inhibitor |
| Remdesivir, favipiravir | • RNA polymerase inhibitors | |
| Hydroxychloroquine | • Not clearly known. Modify pH of endosomes and prevents viral entry, transport and post-entry events | |
| Ivermectine | • Different anti-viral activity | |
| Anti-inflammatory | ||
| Interferon | IFNα inh, IFNβ1a | • IFNα inh, IFNβ1a |
| Monoclonal antibodies |
Tocilizumab/sarilumab/siltuximab Anakinra Gimsilumab Thalidomide |
• Anti-IL-6 • Anti-IL-1 • Anti-GM-GSF • Anti-TNFα |
| Anti gout | Colchicine | • Tubulin disruption |
| Antibiotics | Azithromycin, clarithromycin | • Protease inhibitors (?) |
| Reduce organ failure | Losartan | • RAAS inhibitor |
| Immune modulation regeneration | Mesenchymal stem cells | |
| Pulmonary complications | AiRuiKa | • PD-1 inhibitor |
| Avastin | • VEGF inhibitor | |
| iNO/Sildenafil | • Pulmonary smooth muscle | |
| Passive immunity | Convalescent plasma | • Passive immunization |
| Active immunity | Vaccines | • Anti-SARS-CoV-2 |
RAAS renin–angiotensin–aldosterone system, iNO inhaled Nitric Oxide